The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis
Open accessAbstract
The tumor-suppressor p53 can induce various biological responses. Yet, it is not clear whether it is p53 in vivo promoter selectivity that triggers different transcription programs leading to different outcomes. Our analysis of genome-wide chromatin occupancy by p53 using chromatin immunoprecipitation (ChIP)-seq revealed 'p53 default program', that is, the pattern of major p53-bound sites that is similar upon p53 activation by nutlin3a, reactivation of p53 and induction of tumor cell apoptosis (RITA) or 5-fluorouracil in breast cancer cells, despite different biological outcomes. Parallel analysis of gene expression allowed identification of 280 novel p53 target genes, including p53-repressed AURKA. We identified Sp1 as one of the p53 modulators, which confer specificity to p53-mediated transcriptional response upon RITA. Further, we found that STAT3 antagonizes p53-mediated repression of a subset of genes, including AURKA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921
A Global Map of p53 Transcription-Factor Binding Sites in the Human Genome
Wei, C.-L., Wu, Q., Vega, V. B., Chiu, K. P., Ng, P., Zhang, T., Shahab, A., Yong, H. C., Fu, Y., Weng, Z., et al. (2006) · Cell · doi:10.1016/j.cell.2005.10.043 · Cited by 1,141
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Self-citationDing, K., Lu, Y., Nikolovska-Coleska, Z., Wang, G., Qiu, S., Shangary, S., Gao, W., Qin, D., Stuckey, J., Krajewski, K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051122a · Cited by 702
The expanding universe of p53 targets
Menendez, D., Inga, A., & Resnick, M. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2730 · Cited by 568
Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo
Wei, G., Badis, G., Berger, M. F., Kivioja, T., Palin, K., Enge, M., Bonke, M., Jolma, A., Varjosalo, M., Gehrke, A. R., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.106 · Cited by 568 · cited 1×
“ChIP in MCF7 cells, library preparation, massive parallel sequencing and ChIP-Seq primary analysis was performed as previously published.(34) Sc-126 (Santa-Cruz Biotechnology, Santa Cruz, CA, USA), Genespin DO-1 p53 and Sc-2025 mouse IgG antibodies were used for IP.”
Methodp53 and E2f: partners in life and death
Polager, S., & Ginsberg, D. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2718 · Cited by 498
Research works printed but not linked: 28
- Goh AM, Coffill CR, Lane DP . The role of mutant p53 in human cancer. J Pathol 2011; 223: 116–126. · DOI · Paper page
- Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004; 10: 1321–1328. · DOI · Paper page
- Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008; 13: 454–463. · DOI · Paper page
- Enge M, Bao W, Hedstrom E, Jackson SP, Moumen A, Selivanova G . MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 2009; 15: 171–183. · DOI · Paper page
- Vousden KH, Lu X . Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594–604. · DOI · Paper page
- Smeenk L, van Heeringen SJ, Koeppel M, van Driel MA, Bartels SJ, Akkers RC et al. Characterization of genome-wide p53-binding sites upon stress response. Nucleic Acids Res 2008; 36: 3639–3654. · DOI · Paper page
- Dell'Orso S, Fontemaggi G, Stambolsky P, Goeman F, Voellenkle C, Levrero M et al. ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promoters. OMICS 2011; 15: 305–312. · DOI
- Sampath D, Rao VA, Plunkett W . Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003; 22: 9063–9074. · DOI · Paper page
- Grinkevich VV, Nikulenkov F, Shi Y, Enge M, Bao W, Maljukova A et al. Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell 2009; 15: 441–453. · DOI
- Blankenberg D, Von Kuster G, Coraor N, Ananda G, Lazarus R, Mangan M et al. Galaxy: a web-based genome analysis tool for experimentalists. Curr Protoc Mol Biol 2010; Unit 19.10: 1–21.
- Kel A, Konovalova T, Waleev T, Cheremushkin E, Kel-Margoulis O, Wingender E . Composite module analyst: a fitness-based tool for identification of transcription factor binding site combinations. Bioinformatics 2006; 22: 1190–1197. · DOI
- Kitagawa M, Aonuma M, Lee SH, Fukutake S, McCormick F . E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Oncogene 2008; 27: 5303–5314. · DOI
- Lee SH, Kim JW, Lee HW, Cho YS, Oh SH, Kim YJ et al. Interferon regulatory factor-1 (IRF-1) is a mediator for interferon-gamma induced attenuation of telomerase activity and human telomerase reverse transcriptase (hTERT) expression. Oncogene 2003; 22: 381–391. · DOI
- Shi L, Ko S, Kim S, Echchgadda I, Oh TS, Song CS et al. Loss of androgen receptor in aging and oxidative stress through Myb protooncoprotein-regulated reciprocal chromatin dynamics of p53 and poly(ADP-ribose) polymerase PARP-1. J Biol Chem 2008; 283: 36474–36485. · DOI
- Nguyen TT, Cho K, Stratton SA, Barton MC . Transcription factor interactions and chromatin modifications associated with p53-mediated, developmental repression of the alpha-fetoprotein gene. Mol Cell Biol 2005; 25: 2147–2157. · DOI
- Naruganahalli KS, Lakshmanan M, Dastidar SG, Ray A . Therapeutic potential of Aurora kinase inhibitors in cancer. Curr Opin Investig Drugs 2006; 7: 1044–1051.
- Zawacka-Pankau J, Grinkevich VV, Hunten S, Nikulenkov F, Gluch A, Li H et al. Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer. J Biol Chem 2011; 286: 41600–41615. · DOI
- van Leeuwen IM, Higgins M, Campbell J, Brown CJ, McCarthy AR, Pirrie L et al. Mechanism-specific signatures for small-molecule p53 activators. Cell Cycle 2011; 10: 1590–1598. · DOI
- Secchiero P, Melloni E, di Iasio MG, Tiribelli M, Rimondi E, Corallini F et al. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. Blood 2009; 113: 4300–4308. · DOI
- Shaked H, Shiff I, Kott-Gutkowski M, Siegfried Z, Haupt Y, Simon I . Chromatin immunoprecipitation-on-chip reveals stress-dependent p53 occupancy in primary normal cells but not in established cell lines. Cancer Res 2008; 68: 9671–9677. · DOI
- Smeenk L, van Heeringen SJ, Koeppel M, Gilbert B, Janssen-Megens E, Stunnenberg HG et al. Role of p53 serine 46 in p53 target gene regulation. PLoS One 2011; 6: e17574. · DOI · Paper page
- Jackson P, Mastrangelo I, Reed M, Tegtmeyer P, Yardley G, Barrett J . Synergistic transcriptional activation of the MCK promoter by p53: tetramers link separated DNA response elements by DNA looping. Oncogene 1998; 16: 283–292. · DOI
- Ptashne M . Principles of a switch. Nat Chem Biol 2011; 7: 484–487. · DOI
- Wang B, Xiao Z, Ren EC . Redefining the p53 response element. Proc Natl Acad Sci USA 2009; 106: 14373–14378. · DOI
- Zhu LJ, Gazin C, Lawson ND, Pages H, Lin SM, Lapointe DS et al. ChIPpeakAnno: a bioconductor package to annotate ChIP-seq and ChIP-chip data. BMC Bioinformatics 11: 237. · DOI · Paper page
- Bailey TL, Elkan C . Fitting a mixture model by expectation maximization to discover motifs in biopolymers. Proc Int Conf Intell Syst Mol Biol 1994; 2: 28–36.
- Hoh J, Jin S, Parrado T, Edington J, Levine AJ, Ott J . The p53MH algorithm and its application in detecting p53-responsive genes. Proc Natl Acad Sci USA 2002; 99: 8467–8472. · DOI · Paper page
- Kel AE, Gossling E, Reuter I, Cheremushkin E, Kel-Margoulis OV, Wingender E . MATCH: a tool for searching transcription factor binding sites in DNA sequences. Nucleic Acids Res 2003; 31: 3576–3579. · DOI · Paper page
Cited by
The multiple mechanisms that regulate p53 activity and cell fate
Hafner, A., Bulyk, M. L., Jambhekar, A., & Lahav, G. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0110-x · Cited by 1,129
Census and evaluation of p53 target genes
Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971
iRegulon: From a Gene List to a Gene Regulatory Network Using Large Motif and Track Collections
Janky, R., Verfaillie, A., Imrichová, H., Van de Sande, B., Standaert, L., Christiaens, V., Hulselmans, G., Herten, K., Naval Sanchez, M., Potier, D., et al. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003731 · Cited by 900
“When extending the analysis and including target genes recently reported in literature [58,59,68], it becomes clear that most overlap coincides within this metatargetome (34/44) (Table S6).”
BackgroundProteogenomic Characterization of Endometrial Carcinoma
Dou, Y., Kawaler, E. A., Cui Zhou, D., Gritsenko, M. A., Huang, C., Blumenberg, L., Karpova, A., Petyuk, V. A., Savage, S. R., Satpathy, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.01.026 · Cited by 485
“The mutationtype-specific effects described above appear to be unique to EC; we examined the CPTAC data for ovarian and colon cancer, where TP53 mutations are very common, but observed no change in AURKA, CDK1, XPO1, or STK11 protein levels associated with the type of TP53 mutation (Figure S3H).”
BackgroundInfluentialSelf-citationKenzelmann Broz, D., Spano Mello, S., Bieging, K. T., Jiang, D., Dusek, R. L., Brady, C. A., Sidow, A., & Attardi, L. D. (2013) · Genes & Development · doi:10.1101/gad.212282.112 · Cited by 443
Metadata
- Authors
- Nikulenkov, F., Spinnler, C., Li, H., Tonelli, C., Shi, Y., Turunen, M., Kivioja, T., Ignatiev, I., Kel, A., Taipale, J., & Selivanova, G.
- Venue
- Cell Death & Differentiation
- Published
- 2012-07-13
- Volume
- 19
- Issue
- 12
- Pages
- 1992-2002
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- OpenAlex
- W1982718063
- Cited by
- 181
- References
- 10
- FWCI
- 11.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
